All biotechs don't all crash. Some do, some don't. Many flourish and become the biggest winners in the stock market. The ones that successfully develop a drug can be 10X or 20X baggers.
It's moot on this board anyway, because ABC isn't a biotech. You can skip calling everyone morons too. It only highlights your own shortcomings when you try to debate subjects above your knowledge level.
It seems that you don't know what ABC does. ABC isn't your typical biopharma. It distributes and packages other companies' drugs and equipment, rather than developing and selling its own product lines; therefore, ABC doesn't have the downside of R&D expenses, failed trials, and patent expirations.
ABC's forward P/E is under 14, and it made 52 cents per share last quarter on more than $19 B in revenue. And it has $3.45 in cash per share.
When you're equating ABC to another company, think MHS rather than an INSM or even a BMY.